Treatment characteristics
| No. of cycles | Patients | |||
|---|---|---|---|---|
| n = 44 (%) | ||||
| 1 | 5 (11) | |||
| 2 | 12 (27) | |||
| 3 | 2 (5) | |||
| 4 | 25 (57) | |||
| Dose modifications | ||||
| No. of patients (%) | No. of cycles (%) | |||
| IL-2/IFNa | ||||
| 50% reduced | 14 (32) | 21 (16) | ||
| Discontinued | 5 (11) | 5 (4) | ||
| DTIC/VBLb,c | ||||
| 25% reduced | 13 (30) | 18 (14) | ||
| 50% reduced | 6 (14) | 6 (5) | ||
| CDDPd | ||||
| 25% reduced | 5 (11) | 10 (8) | ||
| 50% reduced | 0 (0) | 0 (0) | ||
a IL-2/IFN: modified for hypotension, neurotoxicity (1), or cardiac (1).
b VBL, vinblastine.
c DTIC/VBL: modified for hematological toxicity.
d CDDP: modified for nausea/vomiting.